Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Collaborative quality improvement initiative to enhance adult asthma management
Sharma, Ramona , Brandse, Selina K , Riffle, Terri L

BMJ Open Quality | May 26, 2025 | Volume: 14 | Issue: 2 | Pages: e003265

10.1136/bmjoq-2024-003265 | PMID 40425204 Get It

Background Adult asthma is a prevalent chronic condition that is suboptimally managed in primary care settings. Local problem Uncontrolled asthma rates were noted in our local clinic where adult patients with asthma receive care. Methods We used a structured intervention to improve adult asthma management, with the primary objective of increasing the percentage of patients at our clinic with an updated Asthma Action Plan (AAP) during a 1-year period. Data were collected through electronic health record audits and patient surveys and were analysed by using run charts. This quality improvement initiative was based on the chronic care model, which emphasises self-management support, clinical decision support and clinic systemic changes. Intervention An approach involving a multidisciplinary team (ie, clinicians, nurses, panel managers and front desk personnel) was used to increase the percentage of adult patients (18–50 years old) at our clinic with an updated AAP (ie, reviewed within the past 12 months). The 1-year intervention period was from February 2023 through January 2024. The nursing team reviewed patients’ problem lists to ensure updated information. In addition, the Asthma Management Questionnaire and Asthma Control Test were pushed through the patient portal for previsit completion or were administered during the rooming process by nursing staff. During the visit, clinicians followed up with patients to complete an AAP. Results Adherence to asthma management guidelines was improved during the intervention period. The percentage of patients with updated AAPs increased from 7.5% (n=120) in February 2023 to 43.4% (n=152) in January 2024. The percentage of patients with optimal asthma control also increased from 40.0% (n=120) in February 2023 to 55.2% (n=165) in August 2023 and 66.4% (n=152) in January 2024. Conclusions This quality improvement project led to measurable improvements in asthma care, highlighting the effectiveness of a structured intervention in the primary care setting.
Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson’s disease
Qin, Bingqing , Fu, Yuan , Kong, Shuangyu, Li, Han , Liu, Chunfeng, Zhao, Jing , Raulin, Ana‐Caroline , Kong, Shuangyu, Liu, Junyi

Chinese Medical Journal | May 26, 2025 | Volume: 138 | Issue: 12 | Pages: 1411-1423

10.1097/cm9.0000000000003627 | PMID 40419446 Get It

Abstract Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of Lewy bodies, leading to motor and nonmotor symptoms. While both genetic and environmental factors contribute to PD, recent studies highlight the crucial role of lipid metabolism disturbances in disease progression. Altered lipid homeostasis promotes protein aggregation and oxidative stress, with significant changes in lipid classes such as sphingolipids and glycerolipids observed in patients with PD. These disturbances are involved in key pathological processes, such as α-synuclein aggregation, organelle dysfunction, lipid-mediated neuroinflammation, and impaired lipid homeostasis. This review examines the relationship between lipid species and PD progression, focusing on the physiological roles of lipids in the central nervous system. It explores the mechanistic links between lipid metabolism and PD pathology, along with lipid-related genetic risk factors. Furthermore, this review discusses lipid-targeting therapeutic strategies to mitigate PD progression, emphasizing the potential of lipid modulation for effective treatment development.
Long-term outcomes and radiation-induced complications following stereotactic radiosurgery for a left temporal arteriovenous malformation: illustrative case
Mansour, Moustafa , El-Salamoni, Mohamed Abdel-Fattah, Mostafa, Hamdi Nabawi , Mansour, Moustafa A

Journal of Neurosurgery: Case Lessons | May 26, 2025 | Volume: 9 | Issue: 21 | Pages: No page available

10.3171/case25201 | PMID 40418888 Get It

BACKGROUND Cerebral arteriovenous malformations (AVMs) are complex vascular anomalies associated with significant risks of hemorrhage and neurological deficits. Stereotactic radiosurgery (SRS) has emerged as a viable treatment option, particularly for small, deep-seated, or eloquent lesions, offering a less invasive alternative to microsurgical resection. However, SRS carries risks, including radiation-induced complications such as radiation necrosis. OBSERVATIONS This report describes the case of a 24-year-old male with a left temporal AVM, classified as Spetzler-Martin grade II, who underwent SRS with a marginal dose of 18 Gy. Over a 36-month follow-up period, complete obliteration of the AVM nidus was achieved. However, significant radiation-induced complications emerged, including vasogenic edema, radiation necrosis, memory deficits, partial seizures, and bilateral visual field defects. These complications peaked around 20 months post-SRS, requiring long-term management with corticosteroids, diuretics, and anticonvulsants. LESSONS This case underscores the importance of balancing the benefits of AVM obliteration with the risks of radiation-induced injury. While SRS is effective for treating AVMs, particularly in high-risk locations, the potential for delayed complications highlights the need for careful patient selection, meticulous treatment planning, and long-term follow-up. The report also discusses the pathophysiology of radiation-induced necrosis, strategies to mitigate its risk, and the role of advanced imaging techniques in optimizing treatment planning. https://thejns.org/doi/10.3171/CASE25201
Determinants and clinical impact of time to plasma exchange in patients with immune thrombotic thrombocytopenic purpura
Tatake, Ishan , Wilkinson, Shelby C., Ruby, Kristen N. , Collins, Julia , Dzik, Sunny , Uhl, Lynne , Stowell, Sean R. , Langer, Arielle L. , Makar, Robert S. , Bendapudi, Pavan K. , Tatake, Ishan J , Dzik, Walter H , Stowell, Sean , Langer, Arielle , Ruby, Kristen N , Carney, Brian J.

Transfusion | May 26, 2025 | Volume: 65 | Issue: 7 | Pages: 1242-1250

10.1111/trf.18291 | PMID 40418719 Get It

AbstractBackgroundImmune thrombotic thrombocytopenic purpura (iTTP) is a hematologic disorder characterized by severe acquired deficiency in ADAMTS13, resulting in thrombotic microangiopathy and death if untreated. Plasma exchange (PLEX) is the backbone of iTTP management and has improved survival in this disorder. Guidelines suggest initiation of PLEX within 4–8 h of presentation; however, there is little evidence to guide the precise timing of PLEX, and barriers exist to its timely deployment.Study design and methodsWe examined determinants of time between symptom onset to PLEX initiation (S2P) and hospital presentation to PLEX initiation (door to PLEX, D2P) in a large iTTP research cohort at an academic medical center.ResultsIn 225 cases occurring in 143 unique patients, the median (IQR) S2P time was 4.28 (1.92–7.47) days. In linear mixed effects regression analysis, increased S2P was associated with greater distance from a participating apheresis center (p = .01) and higher presenting platelet count (p = .046), while relapse presentation was associated with shorter S2P (p = .036). The median (IQR) D2P time was 8.4 (5.03–15.63) h. Longer D2P time was associated with a higher presenting platelet count (p = .002) and trended towards association with male sex (p = .057). Increased S2P and D2P times were not associated with hospital length of stay, mortality, or the composite of mortality and ICU stay.ConclusionOur data show that different factors contribute to the interval between symptom onset and presentation versus the time between presentation and initiation of therapy in iTTP.
Vascular Medicine Patient Information Page: What is a vascular medicine specialist?
Damani, Devanshi N. , Gray, Bruce H. , Levy, Michael S. , Gornik, Heather L. , Beckman, Joshua A , Gray, Bruce , Gornik, Heather L , Damani, Devanshi , Beckman, Joshua A. , Hamburg, Naomi M.

Vascular Medicine | May 26, 2025 | Volume: 30 | Issue: 4 | Pages: 525-529

10.1177/1358863x251343051 | PMID 40418658 Get It

Vasopressin V1a and V1b receptor antagonism does not affect the efficacy of tolvaptan in polycystic kidney disease
Nanayakkara, K.D.L. , Hu, Jinghua , Nanayakkara, Kavini , Hu, Jinghua , Torres, Vicente E , Wang, Xiaofang , Li, Jiang , Torres, Vicente E.

American Journal of Physiology-Renal Physiology | May 26, 2025 | Volume: 329 | Issue: 1 | Pages: F20-F31

10.1152/ajprenal.00350.2024 | PMID 40418559 Get It

Currently, the vasopressin V2 receptor antagonist tolvaptan is the only approved treatment for autosomal dominant polycystic kidney disease (ADPKD). It has been suggested that vasopressin acting on V1a or V1b receptors may also affect its development. We show that a V1aR antagonist has no effect in an ADPKD mouse model (Pkd1RC/RC), whereas a V2R antagonist has a modest attenuating effect in female mice only. Neither potentiates or hinders the beneficial effect of tolvaptan when administered in combination with this drug.
Reducing the Noise in Plasma Metagenomics to Further Define Clinical Utility
Bosquez, Jennifer M, Graf, Erin H. , Graf, Erin H , Bosquez, Jennifer M.

Clinical Chemistry | May 26, 2025 | Volume: 71 | Issue: 7 | Pages: 728-730

10.1093/clinchem/hvaf065 | PMID 40415580 Get It

Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Hawkes, Will, Woodward, Gary , Hamza, Izhan, Desai, Viral , Barrett‐O’Keefe, Zachary , Grogan, Martha, Davison, Halley, Maurer, Mathew S. , Helmke, Stephen , Scherrer‐Crosbie, Marielle , Soltani, Marwa , Goyal, Akash , Zaręba, Karolina M. , Cheng, Richard K. , Vieira, Marcelo Luiz Campos , Elissamburu, Pablo , Ronderos, Ricardo , Prado, Aldo , Sarswat, Nitasha , Addetia, Karima , Ruberg, Frederick L. , Randazzo, Michael , Al-Roub, Nora , Kidd, Liam, Lang, Roberto M. , Pellikka, Patricia A. , Barrett-O'Keefe, Zachary, Scott, Christopher , Davison, Halley N, Cheng, Richard , Kirkpatrick, James N , Koutroumpakis, Efstratios , Deswal, Anita M , Pursnani, Amit , Pellikka, Patricia A , Slivnick, Jeremy A. , Hawkes, Will, OLIVEIRA, JORGE COELHO , Akerman, Ashley, Gómez, Alberto , Grogan, Martha , Dispenzieri, Angela , Scott, Christopher G. , Cotella, Juan Ignacio , Maurer, Mathew S , Kitano, Tetsuji , Takeuchi, Masaaki , Hotta, Viviane Tiemi , Patel, Amit R. , Asch, Federico M. , O’Driscoll, Jamie M. , Strom, Jordan B. , Kidd, Liam, Cuddy, Sarah A. M. , Upton, Ross

European Heart Journal | May 26, 2025 | Volume: 46 | Issue: 40 | Pages: 4090-4101

10.1093/eurheartj/ehaf387 | PMID 40631729 Get It

Abstract Background and Aims Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed. Methods Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness. Results Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores. Conclusions This AI screening model—using only an apical four-chamber view—effectively differentiated CA from other causes of increased left ventricular wall thickness.
What are steroids, and how do they work?
Cutsforth‐Gregory, Jeremy K.

Brain & Life | May 26, 2025 | Volume: 21 | Issue: 3 | Pages: 9-9

10.1097/01.nnn.0001118344.66143.40 Get It

Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder
Roston, Sydney, Quick, Melanie H, Tisavipat, Nanthaya , Tajfirouz, Deena , Chodnicki, Kevin D. , Tillema, Jan‐Mendelt , Kunchok, Amy , Chen, John J. , Tajfirouz, Deena , Pittock, Sean J , Flanagan, E P , Chen, John J , Tisavipat, Nanthaya , Roston, Sydney R. , Quick, Melanie H, Rattanathamsakul, Natthapon , Cacciaguerra, Laura , Flanagan, Eoin P.

Multiple Sclerosis Journal | May 26, 2025 | Volume: 31 | Issue: 10 | Pages: 1247-1253

10.1177/13524585251340841 | PMID 40415648 Get It

Increased intracranial pressure (ICP) is increasingly recognized in myelin oligodendrocyte glycoprotein antibody-associated disease but has not been systematically explored in other demyelinating conditions. This cross-sectional study examines the features of raised ICP in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Lumbar puncture opening pressure (OP) done within 30 days of an attack was identified in 41 NMOSD patients and 37 MS patients. Raised OP was present in 7 (17.1%) NMOSD patients and 4 (10.8%) MS patients who were largely asymptomatic, partially explained by obesity, and did not require ICP lowering medications beyond acute treatment with corticosteroids.